Research programme: Helicobacter pylori infection therapies - AstraZeneca

Drug Profile

Research programme: Helicobacter pylori infection therapies - AstraZeneca

Latest Information Update: 03 Sep 2010

Price : $50

At a glance

  • Originator AstraZeneca
  • Class Pyrazoles; Small molecules
  • Mechanism of Action Glutamate racemase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Helicobacter infections

Most Recent Events

  • 03 Sep 2010 Preclinical development is ongoing in USA
  • 20 Aug 2009 Preclinical pharmacokinetics data presented at the 238th American Chemical Society National Meeting (238th-ACS-2009)
  • 31 Oct 2007 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top